Evotec Buys Bionamics For Shortcut To German Academic Gems
This article was originally published in The Pink Sheet Daily
Executive Summary
In a novel move to overcome the slowdown in outsourcing, small-molecule drug discovery company Evotec has bought asset manager Bionamics to more quickly progress assets originating in German academia.
You may also be interested in...
Evotec Says DiaPep Demise Delays Goals, Spotlight Now On Roche Pact
With the disappearance of DiaPep277 due to presumed fraud, Evotec is now looking to its partnership with Roche in Alzheimer’s to bring the German biotech’s first drug to market - but the timeframe will be longer.
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
MorphoSys: Accelerating The Long Transformation
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.